3.3.5. OSA Analysis

Table 8 shows the OSA results. Sleepiness on rising was significantly higher after 8 weeks of the continuous intake of *Euglena* 500 mg (47.7 ± 9.0) than in the placebo intake group (41.5 ± 5.3) (*p* = 0.027, Dunnett's test); at week 12 after the continuous intake of *Euglena* 500 mg (48.9 ± 10.8) than in the placebo intake group (41.4 ± 7.2) (*p* = 0.027, Dunnett's test); and at week 12 after the continuous intake of *Euglena* 3000 mg (48.3 ± 8.9) than in the placebo intake group (41.4 ± 7.2) (*p* = 0.040, Dunnett's test). These results sugges<sup>t</sup> that the quality of sleep may improve with the intake of *Euglena.*

The "refreshing" index tended to be higher at week 8 after the continuous intake of *Euglena* 500 mg (47.0 ± 8.5) than in the placebo intake group (41.1 ± 4.7) (*p* = 0.055, Dunnett's test). This index was significantly higher in week 12 after the continuous intake of *Euglena* 500 mg (48.4 ± 8.0) than in the placebo intake group (41.6 ± 7.0) (*p* = 0.032, Dunnett's test). This index was significantly higher at week 12 after the continuous intake of *Euglena* 3000 mg (49.0 ± 8.2) than in the placebo intake group (41.6 ± 7.0) (*p* = 0.016, Dunnett's test). These results sugges<sup>t</sup> that the quality of sleep may improve with the intake of *Euglena.*

Sleep length tended to be longer in week 12 after the continuous intake of *Euglena* 500 mg (51.3 ± 9.3) than in the placebo intake group (44.5 ± 7.1) (*p* = 0.060, Dunnett's test). Sleep length tended to be longer in week 12 after the continuous intake of *Euglena* 3000 mg (50.7 ± 10.9) than in the placebo intake group (44.5 ± 7.1) (*p* = 0.089, Dunnett's test). These findings sugges<sup>t</sup> that the quality of sleep may improve with the intake of *Euglena*.
